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BOTOX and Its Effect on Wrinkles
Rochelle Eckstein

ABSTRACT
Clostridia Botulinum (C. Botulinum) is a bacterium that produces a unique exotoxin,
botulinum toxin (BTX). BTX induces flaccid muscle paralysis by inhibiting the release of
acetylcholine at the cholinergic nerve endings. Recently, Botox, developed from BTX, has
become a popular solution to reduce the appearance of hyper-functional facial rhytids. Facial
wrinkles are caused by repetitive muscle contraction, and a treatment that directly addresses this
will be effective. Injections of Botox temporarily relax or paralyze these muscles. This paper will
briefly discuss the bacterial basis of Botox and its development. It will explain how the
mechanism of action of BTX can be used therapeutically and cosmetically as well. The formula
and development of Botox and similar drugs will be explained as well as the relevant facial
anatomy. A detailed analysis of case studies and comparisons of different formulations are
required before determining if Botox is an effective treatment. The side effects and risk factors
involved will be assessed, concluding if Botox is a safe as well as effective treatment.
INTRODUCTION
CLOSTRIDIUM BOTULINUM
Clostridium botulinum, a gram-positive, spore forming, anaerobic bacteria, is found in
the soil but easily isolated (Arnon et al, 2001). C. botulinum is best known for its neurotoxin
produced by growing cells, botulinum toxin, BTX. BTX is the most poisonous of all known
poisons and causes the disease botulinum which is characterized by flaccid muscle paralysis
(Sharma and Shukla, 2005).
C. Botulinum was first discovered in the 1820s by Justinus Kertner, a Bavarian. Kertner
collected data and published two monographs on 230 cases of botulism, giving a complete and
accurate description of botulism including symptoms, duration and physical findings. Symptoms
include: tear fluid disappears, the pupils dilate, eye muscles are paralyzed, mucous and saliva
secretion is suppressed, skin is dry and the skeletal and gut muscles are paralyzed. Cognition is
retained throughout all this (Scott, 2004).
Seventy-five years later, Van Ermengem, a professor of bacteriology correctly described
the bacterial basis of botulism after an outbreak among 34 individuals who had attended a
funeral and eaten raw partially salted ham. Of these, 34, 23 became paralyzed and 3 died. Van
Ermengem found the ham was toxic to lab animals, producing a paralytic disease. He isolated the
anaerobic bacteria from the ham and the spleen of one man who died. He grew it, named it,
characterized its culture requirements and described its toxin (Scott, 2004). Botulinum is from
the Latin botulis, meaning sausage, from the first incidences of botulism caused by sausages
(Boni, Burg, and Kreydan, 2000).
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BOTULISM
Botulism is a rare disease with four naturally occurring syndromes: foodborne, airborne,
infant and wound. The bacteria cannot penetrate unbroken skin, so it must be ingested, inhaled,
or colonized in broken skin (Arnon et al, 2001). The most common form is foodborne botulism
from improperly stored food containing the bacteria. The spores are resistant to heat and survive
when foods are not processed correctly. Once ingested, the bacteria colonize in the GI tract and
secrete BTX. Inhalation botulism is caught via airborne BTX that is inhaled and absorbed
through the lungs. Wound botulism generally occurs in deep wounds associated with IV drug
use. Infant botulism is caused by the ingestion on the bacteria spores that colonize in the GI tract
and secrete toxin that is absorbed from the lumen. Infants have an immature gut physiology and
an inadequate development of gut flora so they are particularly susceptible to infection (Sharma
and Shukla, 2005).
Because of its toxicity, the use of botulism as a biological weapon presents a dangerous
threat. A single gram of crystalized toxin, evenly dispersed and inhaled, could kill more than one
million people (Arnon et al, 2001). However, because of its potency and unique method of
action, BTX also has many therapeutic uses as will be discussed later (Sharma and Shukla,
2005).
BOTULINUM TOXIN (BTX) AND MECHANISM OF ACTION
There are seven distinct serotypes of C. botulism, A-G, that are characterized by
immunological differences in their toxin (Sharma and Shukla, 2005). All toxins have a similar
structure of a large single polypeptide and block the release of acetylcholine at the
neuromuscular junction, causing acute flaccid muscle paralysis (Sobel, 2005).
BTX is synthesized as a single-chain polypeptide with a molecular weight of
approximately 150kDa. The bacteria possess a protease that nicks the molecule to create a
dichain structure, consisting of a heavy chain (100kDa) linked to a light chain (50kDa) by a
disulfide bond. The dichain molecule is the active form of the toxin that blocks cholinergic
transmission (Simpson, 2004). BTX is extremely potent because it is enzymatic (Arnon et al,
2001). The potency is remarkable because the toxin goes through a lengthy and complex chain of
events until it reaches the action site, the peripheral cholinergic nerve endings (Simpson, 2004).
The toxin is released from the bacteria as part of a non-covalent complex together with
auxiliary proteins. These auxiliary proteins have no meaningful role at the site of toxin action.
Their function is to make the toxin resistant to the harsh conditions in the gut like low pH and
proteolytic enzymes. Once the toxin enters the lumen of the gut or airway, it must cross
membrane barriers to reach the general circulation. The toxin does not cause cell death;
therefore, it does not kill the cells in its path. Rather, it uses transmembrane and transcellular
processes to reach its target. A likely mechanism of action has been proposed: the toxin binds to
the apical surface of the epithelial cells, undergoes receptor-mediated endocytosis and
transcytosis and is delivered to the basolateral surface of the cells. The toxin can therefore reach
blood and lymph (Simpson, 2004).
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Once the toxin enters the general circulation, it needs to exit the vasculature to reach the
extracellular space near the cholinergic nerve cells. There is no single study that describes this
exit from the vasculature, but it could be an active transcellular process of para-cellular
movement. Since BTX does not penetrate the blood-barrier, it has little ability to impair central
cholinergic transmission of intact organisms (Simpson, 2004).
When the toxin reaches the peripheral cholinergic nerve endings, there is a sequence of
membrane penetrating events. [Figure 1]
1. The toxin binds to the surface of the plasma membrane
2. This is followed by receptor mediated endocytosis and pH induced translocation
across the endosome membrane
3. When the toxin reaches the cytosol, it acts as a zinc-dependent endoprotease to cleave
polypeptides that are essential for exocytosis
4. This blockade of the transmitter release accounts for the flaccid paralysis that is
characteristic of botulism. Without release of acetylcholine, the muscle cannot
contract.
BTX acts preferentially on cholinergic nerve endings, but can block exocytosis from other nerve
endings, such as norepinephrine and serotonin, when the concentration of the toxin is increased.
While BTX can block exocytosis at all peripheral cholinergic sites, the neuromuscular junction
has received the greatest amount of research and clinical attention (Simpson, 2004). No one has
yet determined how the toxin is eliminated from the nerve endings. However, the nerve terminals
regenerate slowly (Sobel, 2005), and new motor axon twigs sprout to reinervate the paralyzed
muscle fibers (Arnon et al, 2001). This process takes several weeks or months, and in the United
Staes, 96% of those affected eventually fully recover (Sobel, 2005).
Figure 1
Most of the steps in BTX action occur at two sites. Epithelial cells are transport cells; they bind
the toxin and carry it from the lumen of the gut to interstitial fluid and general circulation.
Peripheral cholinergic nerve endings like those at the neuromuscular junction are target cells for
toxin action. BTX binds to these cells and once internalized into the cytosol attacks polypeptides
that are essential for transmitter release (Simpson, 2004).
Steps in Toxin Action
Transport Ce l I
(/
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When BTX is exposed to striated skeletal muscle, it prevents the release of the
acetylcholine (ACh) at the neuromuscular junction (Matarasso, 1998). ACh is the major
neurotransmitter involved in parasympathetic nerve transmission at the post ganglionic synapse.
In skeletal muscles, calcium activates the release of ACh from the presynaptic membrane into
the synapse. ACh then binds to the nicotine receptors on the post synaptic membrane. When the
nicotine receptors are activated by ACh, they allow transport of sodium and potassium ions
across the post synaptic cell membrane. The entry of sodium into the cell causes depolarization
of the cell membrane and generation of an endplate potential. The endplate potential initiates
propagation of an action potential along the cell membrane of the skeletal muscle, ultimately
causing skeletal muscle contraction (Boni, Burg, and Kreydan, 2000). [Figure 2]

Figure 2
BTX is composed of a heavy chain and a light chain linked by disulfide bonds. Once internalized
into the synapse, the light chain dissociates and cleaves the target protein, thus blocking ACh
release (Boni et al, 2000).
The receptor at the neuromuscular junction has not been unequivocally identified. The
major distinction between serotype A and serotype B are that they attack different substrate.
Each serotype cleaves only one peptide bond in its substrate even though the sequence may be
repeated in the substrate. Serotypes C and E are similar to serotype A and types D and F are
similar to type B. (Simpson, 2004). BTX-A cleaves to a 25-kd synaptosome associated protein
(SNAP-25) and BTX-B cleaves to a vesicle-associated membrane protein (VAMP or
synaptobrevin) (Carruthers and Carruthers, 2005). Although they both block ACh release, BTXA blocks the frequency of the spontaneous release by greater magnitude than BTX-B (Simpson,
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2004). This difference may be responsible for differences in clinical effects of the two toxins, as
discussed later (Carruthers and Carruthers, 2005).
HISTORY OF THE THERAPUETIC AND COSMETIC USES OF BTX
BTX is also used therapeutically and cosmetically. When injected, it produces a
temporary chemo-denervation of muscle, resulting in a localized reduction of muscle activity
(Carruthers and Carruthers, 2005). When used to treat conditions where there is excessive and
uncontrolled cholinergic nerve activity, BTX causes temporary relaxation of muscle where
normal function is attained (Simpson, 2004). These potential uses for BTX were not realized
until the 1970s, long after it was considered a biological terror threat. In the 1940s, Drachman of
Johns Hopkins used small doses of toxin to paralyze the hind limbs of chicks. At that time,
alternative therapies were being sought to treat strabismus, such as injections of different
anesthetics, alcohols and snake neurotoxins. Techniques to accurately inject extraocular muscle
with local anesthetics to determine their function in eye movement had already been developed
(Scott, 2004).
The first experimentation on humans began in the 1960s and gained acceptance by the
1990s. Scott investigated therapeutic uses of the toxin first in monkeys and then on humans with
strabismus and blepharospasm (Cote et al, 2005). A few picograms of the toxin injected into the
target muscle induced a paralysis confined to that muscle with long duration and no side effects.
By 1982, the eye muscles were injected for retraction, hemi-facial spasm, blepharospasms and
the limbs and neck for dystonia. At first there was a strong aversion to using BTX for these
indications, but as there was no adequate alternatives to treat many motility disorders, treatment
became more popular (Scott, 2004). In 1989, the FDA approved using BTX-A for treating
strabismus and blepharospasm and in 2000, expanded approval to include cervical dystonia
(Cote et al, 2005). Other conditions were also treated with BTX in the mid-1990s, such as
hyperhidrosis and Frey’s syndrome (Scott, 2004).
Cosmetic use of BTX was pioneered by Alistair and Jean Carruthers. Many patients
treated for blepharospasm would joke at their 3 and 4 month follow up visits that they were there
to “get the wrinkles back out” (Scott, 2004). Carruthers first tested BTX to treat glabellar lines in
1992 and later tested it on selected facial muscles to lift the brow and flatten folds (Carruthers,
2005). In 2002, the FDA approved BTX-A for cosmetic use for temporary improvement to the
appearance of glabellar lines. These lines are the only FDA approved rhtyids for BTX treatment,
but many physicians use it for off-label purposes as well. The most common injection sites are
the glabellar frown lines, crow’s feet, wrinkles, the forehead and neck bands (Cote et al, 2005).
BOTOX
BTX-A is available in two formulas: from Allergan in the United States and Canada as
Botox, and as Dysport in Britain, France, and Germany. BTX-A is sold in a lyophilized form and
needs to be reconstituted with saline before use. BTX-B is available as Myobloc only in the
Unites States and is sold in an aqueous solution. The dosages of all three vary greatly and one
needs to make sure that the correct dosage for the specific product is used as well as adhering to
the manufacturing guidelines (Mantell, 2004). All treatments are temporary and serial doses are
needed to maintain the desired results (Mendez-Eastmen, 2000).
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Botox is available through Allergen and the toxin is supplied in a 100-unit multi-dosed
crystallized complex. The crystalline form must be stored in the freezer at temperatures of -5°C
or lower and should be reconstituted immediately before injection (Mendez-Eastmen, 2000).
Both Dysport and Botox are reconstituted either with preservative free solutions or with normal
saline. When reconstituted with preservative free solutions, the formula should be used within 4
hours, but normal saline retains its potency when refrigerated for 4 weeks. The preservative free
saline is refrigerated at 2°-8°C for a maximum of 4 hours to ensure it remains sterile. Many
physicians use the reconstituted form 4 hours after reconstitution, but the toxin could denature
and jeopardize its sterility (Mendez-Eastmen, 2000). Many patients reported less pain with the
injection after using a saline containing preservative. Higher dosages in smaller volume keeps
the toxin and its effects more localized and allows for more precise placement and little spread
(Mantell, 2004). The mode of measuring toxin strength is paralytic activity in the mouse. One
unit is the amount of toxin that kills 50% of a standardized mouse model when injected
intraperitoneally (Klein, 2004). Patients can be treated in a sitting or lying position, but sitting is
recommended to avoid the toxin spreading to underlying muscles (Boni, Burg, and Kreydan,
2000). The administering physician needs to understand the relevant facial anatomy and only a
physician should administer the injection. Local anesthesia is unnecessary. Patients can resume
normal activity post injection and may take Tylenol if they experience pain. Nonsteroidal antiinflammatory agents should be avoided for 7 days before injection as it could exacerbate the
symptoms of side effects (Klein, 2004). The FDA approved treatment only for glabellar lines,
but Botox is often used for off-label uses as well. The decision to inject Botox in an off-label site
should be the physician’s and he should follow the recommended dosage and be careful not to
give too large of a dose (Mendez-Eastmen, 2000).
Dysport, also from BTX-A, is produced via fermentation and then recovered and
dissolved in aqueous solution. It is provided as an air dried powder and is reconstituted and
diluted with normal saline before use, similar to Botox. It is available in the UK and used
therapeutically for blepharospams, torticollis, pediatric cerebral palsy spacity as well as for
cosmetic purposes to treat facial lines. It is not directly comparable to Botox, but there is a ratio
of about 1:3 or 1:4 units of Botox to Dysport (Markey, 2004). Myobloc, BTX-B, has the FDA
approval to treat cervical dystonia. It is sold in a highly purified liquid formulation from
fermented BTX-B. It contains very little protein or inactive toxin because this could increase the
risk of antibody formation. It is slightly acidic with a pH of 5.6, so a painful, burning sensation is
experienced upon injection. There is no dose determined for cosmetic uses, but a ratio of about
1:125 units of Botox to Myobloc is used (Flynn, 2004).
There are several differences between BTX-A and BTX-B. BTX-B has an increased
radius of diffusion than Botox, creating a more uniform effect. The rate on onset of Myobloc is
also slightly faster, by about a day. Duration of effect is does dependent, but studies comparing
the two show that Myobloc has a shorter effect than Botox. Additionally, Myobloc is very stable
even at room temperature because it is not reconstituted (Flynn, 2004).
Injection into the correct part of the muscle is important to achieve maximum benefits.
The toxin works best when injected into the muscle belly and are usually not superficial because
it easily penetrates muscle (Klein, 2004). Injection by EMG (electromyogrpahic) guidance helps
achieve accurate placement by locating the most active part of the muscle responsible for a
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particular facial line. It determines which muscles are contracting and contributing to the frown.
A combines EMG injection needle is used which requires a larger needle. However, some
physicians feel there is no benefit because the anatomy of the glabella is so reliable. Some use
the EMG needle only for reinjection, but perhaps reinjection would not be necessary if one was
used initially. Additionally, the pattern of muscle activity varies greatly from patient to patient
(Mantell, 2004). When EMG injection is used, the area is cleaned with alcohol and allowed to
evaporate completely. This is because the alcohol can denature the toxin. The patient then
frowns, squints and raises the eyebrows to activate the targeted muscles. A needle is connected
to the EMG unit is inserted. After placement, when the muscle is activated, a sound should be
heard from the EMG machine. The needle is reinserted if no sound is heard (Mantell, 2004).
FACIAL RHYTIDS
Lines and wrinkles in the face are caused by muscle action and contraction. Treatments
such as surgery and implants are only partially effective as they do not address the underlying
cause of excessive lines, glabellar lines and crow’s feet (Boni, Burg, and Kreydan, 2000).
[Figure 3]
Frown lines are caused by the contraction of the frontalis muscle (Boni, Burg, and
Kreydan, 2000). The frontalis is the elevator of the brow. This thin muscle covers a large portion
of the forehead and is not attached to bone. The action of this muscle is to elevate the brow and
wrinkle the forehead. The horizontal creases on the forehead are a direct result of the frontalis
action (Vigliante, 2005). 50-60 units of Botox are used to erase these creases (Matarasso, 1998).
Glabellar frown lines are caused by the contraction of the musculus corrugator
superciliaris at the medial end of the eyebrow (Boni, Burg, and Kreydan, 2000). This is a deep
muscle located against the bone beneath the frontalis and orbicularis oculi muscles. The action
draws the eyebrows medially downward, producing vertical glabellar wrinkles. These lines give
the characteristic appearance of anger, frustration and negative emotions. Known as the
“frowning muscle,” it is the principle muscle used in the expression of suffering (Vigliante,
2005). 30-40 units are used to treat the lines (Matarasso, 1998). This muscle is usually stronger
in men, so a slightly higher dose is necessary (Boni, Burg, and Kreydan, 2000).
The procerus muscle marks a horizontal groove at the base of the nose (Boni, Burg, and
Kreydan, 2000). The primary action of this muscle is to draw the medial angle of the eyebrows
which creates the transverse wrinkles at the bridge of the nose (Vigliante, 2005). Generally 30-40
units are needed to improve this furrow (Matarasso, 1998).
The squeezing action of the musculus orbicular oculi causes crow’s feet, deep
horizontal and oblique furrows at the temporal aspect of each eye (Boni, Burg, and Kreydan,
2000). This muscle a broad, flat muscle, and is the chief muscle surrounding the orbit. Is it the
depressor of the brow and eyelid and forceful contraction induces concentric folds. In childhood,
these lines are seen only in dynamic situations, such as laughter or squinting in the sunlight.
However, in adulthood they are visible even in facial repose. These lines increase with years of
sun exposure and dynamic expression (Vigliante, 2005). 20-30 units are needed to treat them
(Matarasso, 1998).
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The platysma, a broad sheet of muscle, is located in the neck, but is primary function is
on the face
FRONTALIS M.
PROCERUS M.

Figure 3 Hyperfunctional facial lines
from the activation of the muscles of
the upper facial third
(Vigliante , 2005)

and mandible. When the fibers act, the skin over the clavicle is wrinkles and drawn toward the
mandible, increasing the diameter of the neck and causing hyper-functional bands in the neck.
The muscle also acts to draw the lower lip and corner of the mouth laterally and inferiorly,
partially opening the mouth as in an expression of surprise or horror (Vigliante, 2005). These
bands can be treated with multiple injections (Matarasso, 1998).
CASE STUDIES
THE EFFECTS OF BOTOX ON CROW’S FEET
As mentioned above, repetitive contraction of underlying muscles and their action on
the skin produce wrinkles on non-fatty facial areas. Jean Luc Levy, Jean-Jacques Servant and
Elisabeth Jouve of France conducted and experiment to determine the duration of a defined dose
of BTX-A on crow’s feet wrinkles. An objective evaluation of duration of the results of a single
injection was provided. The treatment area was the crow feet wrinkles and adults with bilateral
symmetric crow’s feet were eligible, but those patients who had undergone prior cosmetic
surgery, had health conditions, were breastfeeding or were potentially pregnant were excluded.
The study included 25 female patients from age 31-65, with a mean age of 48. They were
injected at the baseline with 12 units of BTX-A and evaluated at 3, 6 and 9 month intervals.
Clinical photographs were taken at the baseline and during the follow up visits with the eyes
closed at rest. Patients were positioned in front of the VisioFace special measurement bench with
a 3D sensor. 3D microtopography of the skin was recorded with a DermaTop optical 3D in vivo
scanner (Levy et al, 2004).
Patients were asked to evaluate their photographs at baseline (T0) and 9 months (T3) to
score wrinkle reduction. Observers assessed post treatment and pretreatment photographs. They
compared the photographs from the baseline with those from 3 (T1), 6 (T2) and 9 (T3) months
after the injection. The result from these assessments by the patients, the 3D profilometry and the
independent observers all were similar and showed improvement. Only one patients had a side
effect of edema of the lower lid for a month following treatment. The conclusion from this study
was that BTX-A is a safe and effective method for treating crow’s feet with clear improvement
shown at 6 months (Levy et al, 2004). [Figure 4]
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Figure 4: Improvement after one injection at baseline and follow up visits (Levy et al, 2004).
Although the study group for this trial was not so large, the results can be considered
objective because of the impartial observers and 3D photography. While the results were positive
with few reports of side effects, one should remember that the Crow’s feet wrinkles are not a
FDA approved injection site.
COMPARING THE EFFECT OF BOTOX AND OTC CREAMS ON GLABELLAR
RHYTIDS
Another experiment was conducted by Kenneth Beer to compare the safety and
efficacy of BTX-A with topical creams for treating moderate to severe glabellar rhytids. These
lines are the only conditions approved by the FDA for Botox treatment. These over the counter
(OTC) topical products advertise that they are more effective at treating wrinkles than Botox.
This study, a single-center, randomized, investigator blinded parallel study consisted of five
treatment groups: Botox, a placebo saline injection, StriVectin-SD, Wrinkle Relax and
HydroDerm. Females with clinically diagnosed moderate to severe glabellar lines at maximum
frown from the ages of 18-65 were eligible for participation. Criteria for exclusion were
pregnancy, previous eyebrow surgery, use of retinoids, hydroxyl acids or products containing
vitamins A, C and E, 77 participants were randomly placed into one of the treatment groups.
Frowns were assessed both by the patients and a principle investigator, and photographs were
taken of the glabellar region of each subject at maximum frown and rest. The first phase was a
masked phase with follow up visits at 4, 8 and 12 week intervals. This was followed by an openlabel phase where all subjects received open-label Botox injections with a 4 week post injection
follow up (Beer, 2006).
All participants were instructed to maintain their standard facial care for the duration of
the study. Those subjects in the placebo and Botox groups received injections by a staff member
rather than the investigator to maintain the blind. Those assigned to use the topical creams were
told to apply it in the morning and evening, massaging the cream gently over the bridge of the
nose and eyebrows until absorbed completely. At baseline and each follow up visit, subjects
assessed the change in appearance of the wrinkles, the investigator assessed them and
photographs were taken. Patients also completed a facial line outcomes (FLO) questionnaire
related to self-perception. The primary efficacy measure was the investigator’s assessment of
glabellar lines at maximum contraction at the follow up visits. Secondary was the subjects’
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assessment. Botox treatment resulted in significantly reduced wrinkle severity over the topical
creams and placebo. Subjects who received Botox treatment were also more satisfied with the
treatment results than those in the other groups and 90% were satisfied with treatment during the
open-label phase. Side effects were only reported by 3 participants in the StriVectin-SD group
(Beer, 2006). [Figure 5]
This trial was the first that compared the efficacy of Botox to OTC topical creams. The
results indicated do not support the advertising claims made by manufacturers of these creams.
While they may be a more economic choice, their treatments of hyperfunctional lines were not
very different than the placebo. However, the study was not long enough to see the long term
effects and duration of treatment. Additionally, the investigator is associated with Allergen, the
company that manufactures Botox.

Toxin Type A Group: At Maximum Contraction

Placebo Group : At M<1xrmum Contract,on

HydroDerm Group : At Ma,umum Contraction

!wsehne

8Wttks

4 Wee ki Aher Opeo-1.Jbel Phase

StrlVerttn•SD Group : At Ma1amum Contraction

B,u~hne

Wrinkle Relax Group : At Maximum Contraction
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Figure 5: Photographs comparing treatment at baseline, 8 weeks and after the open-label phase.
(Beer, 2006)
COMPARISON OF BOTOX AND DYSPORT ON GLABELLAR LINES
There has been little research directly comparing the two formulations of BTX-A
which may behave differently, Botox (BTX-Aı) and Dysport (BTX-A²). The results and dosages
of both formulations are different and cannot be compared. Phillipa Lowe, Rickie Patniak and
Nicholas Lowe designed a study to compare the results of both formulations. Patients between
18-55 years of age with moderate to severe glabellar lines at maximum contraction as determined
by an investigator were eligible to enroll. Women of childbearing age were required to have a
negative urine pregnancy test result. Criteria for exclusion included: facial cosmetic surgery
planned during the study, visible scars, prior cosmetic surgery that could interfere with
evaluation, history of facial nerve palsy, alcohol abuse, infection at the injection site. 62 patients
were randomly assigned to the two groups (59 completed the study). The mean age was 41 and
they were predominately Caucasian and female. The mean age of the Botox group was higher,
but there were no other major demographic differences (Lowe et al, 2006).
The BTX-Aı group received a dose of 20 units (the FDA approved dose) and the BTXA² received a dose of 50 units (reported to be the optimal dose). The dose was divided between 5
injection points. Patients could continue their normal face care regimen, but should not apply
creams for 4 hours before the follow up visits. Patients were photographed using the modified
1

BoNTA 2

Baseline

Wk2

Wk8

Wk 12

Wk 10
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Figure 6: More prolonged duration of effect at week 16 with BTX-Aı (BoNTAı) than with BTXA² (BoNTA²) (Lowe et al, 2006).
Canfield system during maximum contraction at each visit. Severity of the lines was graded as
none, mild, moderate or severe. The primary outcome measure was improvement of at least 1grade at week 16. Other outcome measures included patients whose lines were graded as none or
mild and incidence of relapse. Using masked assessment of the standard photographs
demonstrated that BTX-Aı offers a more prolonged efficacy than BTX- A². Both groups peaked
at week 8 for at least a 1-grade improvement. However, the duration of improvement was
generally more prolonged with Botox than with Dysport at week 16. Patient satisfaction was also
higher with Botox than with Dysport. Both products were well tolerated and there was no
difference in treatment related adverse effects between the two groups (Lowe et al, 2006).
[Figure 6]
This study was supported by an unrestricted research grant from Allergen. Furthermore,
the age difference between the two groups is considerably significant as younger patients have
stronger muscles and may require a higher dosage. While Botox may have a longer duration than
Dyspoty, both formulas appear to be effective. Costs cannot be compared because Dysport is not
available in the US and Botox is not in the UK.
SIDE EFFECTS AND COMPLICATIONS WITH BTX-A TREATMENT
Botox is a safe, effective treatment without serious side effects. When it is used properly,
the complications are a few with mild severity. No irreversible clinical effects have been
reported from cosmetic uses. Different treatment areas are associated with different side effects.
The most common complication is ptosis of the upper eyelid from injection into the glabellar
area, but this could be resolved with eye drops. Eyelid ptosis can be avoided with more accurate
placement and lower volume. The most significant complication from treating the frontalis is
brow ptosis. The brow shape may also be changed because the muscle responsible for brow
elevation is relaxed. To avoid this, the forehead and glabella should not be treated in the same
session. Furthermore, the boundaries of the forehead should be defined and injections should not
be above the middle brow. This treatment also works best on younger patients (20-45 years of
age) and older ones should be injected more cautiously. Reported complications from treatment
of Crow’s feet include diplopia, drooping lateral lower eyelid and an asymmetric smile from
injections placed too low, and this takes longer to resolve than lid ptosis. Strabismus is a very
rare side effect, and the patient should be referred to an ophthalmologist for appropriate care.
High doses injected into the platysma can produce weakness and dysphagia. Patients with severe
over treatment of the neck can have trouble holding their necks erect because the muscles are so
weakened. Therefore, injection in any area should be administered carefully in the correct
dosage, in the appropriate location and by an experiences physician. (Klein, 2004).
As part of its mission to improve patient and consumer safety, in 2005, the FDA funded
Cote et al (2005) to conduct a study reviewing the adverse effects (AE) reported to the FDA after
BTX-A treatment. The FDA received reports of AEs through the MedWatch system. Although
clinicians are encouraged to report incidences of AEs, it is voluntary, so the number reported is
actually only a subset if the incidences that occur. It is very difficult to accurately classify the
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AEs into serious and non-serious reports as MedWatch often lacks complete information. AEs
that met the US Code of Federal Regulations 600.80 such as: “death, a life threatening adverse
drug experience, in-patient hospitalization or prolongation of existing hospitalization, a persistent
or significant disability/incapability, or a congenital anomaly/birth defect” were categorized as
serious. All other were referred to as non-serious (Cote et al, 2005).
Cote et al (2005) attempted to review all reported cases, both from therapeutic and
cosmetic use. Serious AEs were reviewed from December 1989 and May 2003. Due to the large
number of non-serious reports, the review was limited from December 2001 to November 2002.
1437 AEs were reviewed, 406 from therapeutic cases and 1031 in cosmetic instances. The
proportion of reports classified as serious was higher for therapeutic cases than those cosmetic
uses. 217 serious AEs were reported for therapeutic cases that included 28 deaths and 17
seizures. For cosmetic cases, there were 36 serious reports and no deaths. The AEs reported were
both known and unknown and for both on-label and off-label uses. The most common reactions
were: dysphagia, muscle weakness, allergic reactions, flu-like syndromes, injection site trauma,
arrhythmia and myocardial infarction. Non-serious reactions included ptosis and headaches for
cosmetic uses. The AEs reported for therapeutic uses were different than those for cosmetic uses
since doses are higher for therapeutic purposes and patients have serious underlying diseases that
increase the risk of an adverse reaction. Many of the AEs in cosmetic cases were related to
improper technique, storage or dilution, higher doses than recommended and injection in sites
that are not FDA approved (Cote et al, 2005).
As in any treatment, there are always side effects involved. However, when used properly
as advised in the approved labeling, the AEs experienced are generally non-serious and plausible
as BTX blocks muscle contraction, so ptosis and dysphagia are likely. Incidences of AEs also
decrease when the optimal dose of 20 units is used (Cote et al, 2005).
There is the possibility of developing resistance to BTX because of antibodies produced
against the toxin. The likelihood of developing immunoresistance is associated with high doses
and greater frequency of treatment (Klein, 2004). All BTX preparations (Botox, Dysport,
Myobloc) have complex mixtures of various proteins and excipients such as human serum
albumin, lactose, NaCI or buffers. Theoretically, all non-human proteins in the mixture can act as
antigens to stimulate formation of antibodies. The antibodies can be formed against the toxin or
non-toxin. Only the antibodies against the toxin interfere with the activity of the toxin and there
may be partial or complete therapy failure (Dressler and Hallett, 2006). The newer batches of
Botox have a decreased amount of protein so chances of antibody production are reduced. The
only effect of these antibodies is that BTX-A is no longer effective, but no hypersensitive
reaction develop (Klein, 2004). Patients who develop antibodies against BTX-A can be treated
with BTX-B as an alternative since the antibodies are antigen specific (Scott, 2004).
CONCLUSION
Botox is a safe, effective and minimally invasive procedure used to reduce the
appearance of hyper-functional facial lines. Although it successfully treats a large part of facial
lines, the only FDA approved injection site is the glabellar frown lines. There are still ongoing
trials to determine the safest and most optimal dosage for the longest duration of effect, but until
then, serial injections are needed to maintain the results. Caution should be used with repetitive
injections as this increases the risk of side effects and developing immunoresistance. Individuals
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should understand the risks involved with Botox injection and consult a physician to determine if
this procedure is right for them.
SUMMARY
As this paper has shown, Botox is an effective treatment to temporarily reduce the
appearance of facial wrinkles. It is processed from diluted bacterial exotoxin, BTX. BTX acts on
the peripheral cholinergic nerve endings to inhibit acetylcholine release and induce flaccid
muscle paralysis. Botox uses this same method to temporarily relax targeted muscles in the face
responsible for wrinkles. Numerous case studies done over the past several years have proven
that Botox is an effective, albeit temporary, alternative to reconstructive surgery to treat and
reduce the appearance of these lines. As with any treatment, there are always risk factors
involved. By adhering to the recommended FDA guidelines of storage, dosage and procedure,
many of these risks are avoided. Patients who opt to receive Botox injections should make sure
to choose an experienced physician to ensure a safe and quality result.
REFERENCES
, S. S., Schechter , R., Inglesby, T. V. , Henderson, D. A., Bartlett, J. G., Ascher, M. S., et al. (2001). Botulinum toxin as a
biological weapon . The Journal of the American Medical Association, 285(8), 1059-1070. Retrieved from
http ://www .jama .com
.
Beer , K. R. (2006) . Comparative evaluation of the safety and efficacy ofbotulinum toxin type A and topical creams for treating
moderate-to-severe glabellar rhytids [Electronic version]. Dermatologic Surgery, 32, 184-92 .
.
Boni , R., Kreyden , O. P ., & Burg, G. (2000). Revival of the use of the botulinum toxin : application _in dermatology [Electroruc
version]. Dermatology, 200(4 ), 287-91.
Carruthers , A., & Carruthers, J. (2005) . Botulinum toxin type A [Electronic version]. Journal of the American Academy of
Dermatology , 53(2), 284-90.
Corcoran, T. (2004). Myobloc [Electronic version] . Dermato/ogic Clinics, 22(2) , 207-11.
.
. . .
Cote, T. R., Mohan , A. K. , Polder , J. A., Walton, M . K. , & Braun, M. M. (2005). Botulinum toxm type A rnJectJons: adverse
events reported to the US Food and Drug Adminstration in therapeutic and cosmetic cases . Journal of the American
Academy of Dermatology, 53(3). Retrieved from http:/ /www .mdconsult.com
.
.
Dressler , D., & Hallet , M . (2006). Immunological aspects ofBotox, Dysport and Myobloc/Neurobloc [Electroruc vers10n].
European Journal of Neurology, 13(Suppl. 1), 11-15.
Klein A. W. (2004). Complications with the use ofbotulinum toxin [Electronic version]. Dermatologic Clinics, 22(2) , 197-205 .
Levy,' J. L., Servant, J.-J., & Jouve , E. (2004). Botulinum toxin A: a 9-month clinical and 3D in vivo profilometric crow 's feet
wrinkle formation study [Electronic version] . Journal of Cosmetic and Laser Therapy, 6, 16-20.
Lowe , P ., Patnaik , R., & Lowe , . (2006 ). Compari on of two formulations ofbotulinum toxin type A for the treatment of
glabe llar line s: a double-blind , randomized study . Journal of the American Aca demy of Dermatolo gy, 55(6). Retri eved
from http ://www.mdconsult.com
Mantell , A. M . (2004) . Dilution , storage, and electromyographic guidance in the use ofbotulinurn toxin [Electronic version].
Dermatolo gic Clinics, 22(2), 135-36 .
Markey , A. C . (2004) . Dy port [Electronic version] . Dermatologi c Clinics, 22(2) , 213-19 .
Matarasso , S. L. ( 1998) . The role of clostridiurn botulin um: a neurotoxin in clinical dermatology. Western Journal of Medicine,
169(4) , 226 . Retrieved from http ://www.proquest.umi .com
Mendez , S. K . (2000) . Botox : a review . Plasti c Surgi cal Nursing, 20(2), 60-68. Retrie ved from http: //www.proquest.umi .com
Scott , A. 8. (2004) . Development ofbotulinum toxin therapy [Electronic version]. Dermatologi c Clinics, 22(2) , 131-133 .
·
Shukla , H . D., & Sharma, S. K. (2005). Clostridium botulinum: a bug with beauty and weapon. Critical Reviews in Microbiolo gy,
31(1), 11-19 . Retrieved from http :// www .proquest.umi .com
Simpson , L. L. (2004). Identification of the major steps in botulinurn toxin action [Electronic version]. The Annual Review of
Pharmi cology and Toxicology , 44, 167-193 .
Sobel , J. (2005) . Botulism . Clinical Infectious Dis eases, 41(8) , 1167-1174 . Retr ieved from http :// www.proquest.umi.com
Vig liant e, C. E. (2005). Anatomy and functions of the muscles of facial expression . Oral and Maxillofa cial Clinics of North
America, 17(1). Retrieved from http: //www.mdconsult.com

83

